ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-18 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 96.6 KB | ||
| 2024-11-27 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | 96.9 KB | ||
| 2024-11-19 22:30 |
Abivax met en place un programme « At-the-Market (ATM) » sur le Nasdaq
|
French | 154.9 KB | ||
| 2024-11-19 22:30 |
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
|
English | 22.0 KB | ||
| 2024-11-14 22:01 |
Abivax présente les principales informations financières du troisième trimestre…
|
French | 258.3 KB | ||
| 2024-11-13 22:01 |
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Obse…
|
English | 10.3 KB | ||
| 2024-11-08 17:38 |
Franchissement de seuil et déclaration d'intention
|
French | 337.2 KB | ||
| 2024-10-11 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 97.2 KB | ||
| 2024-10-11 18:00 |
ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contrac…
|
English | 85.2 KB | ||
| 2024-10-11 18:00 |
ABIVAX annonce la résiliation de son contrat de liquidité et présente le bilan …
|
French | 86.4 KB | ||
| 2024-10-07 22:01 |
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the…
|
English | 9.7 KB | ||
| 2024-10-03 22:01 |
Abivax annonce le recrutement d'un premier patient dans Enhance-CD, l'essai cli…
|
French | 110.1 KB | ||
| 2024-10-03 22:01 |
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Ob…
|
English | 10.9 KB | ||
| 2024-10-03 08:30 |
Résultats positifs d'une analyse intermédiaire portant sur l'efficacité et la t…
|
French | 129.2 KB | ||
| 2024-10-03 08:30 |
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg…
|
English | 12.5 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
